CVS Caremark will resume covering Eli Lilly’s weight loss drug Zepbound after removing it from its covered medications list last year, Lilly said. The coverage is set to restart this year, with CNBC reporting that CVS will restore Zepbound coverage on October 1. In addition to bringing back Zepbound, CVS plans to expand its drug plans by covering Lilly’s newly approved obesity pill, which CNBC reports will begin on June 1. The reporting is based on statements from Eli Lilly describing the change to CVS Caremark’s formulary coverage. NBC’s account focuses on the reinstatement of Zepbound, while CNBC adds specific dates and also includes the timeline for coverage of Lilly’s other obesity medication. Both sources indicate that CVS Caremark’s coverage decisions for Lilly’s obesity-related treatments are changing again in 2024, reversing last year’s removal of Zepbound.